PR Newswire/Les Echos/
PRESS RELEASE
Sanofi appoints David Loew, Senior Vice President, Commercial Operations,
Europe
Paris, France - May 23, 2013 - Sanofi (EURONEXT : SAN and NYSE : SNY) is pleased
to announce today the appointment of David Loew, as Senior Vice President,
Commercial Operations, Europe, effective July 1st , 2013. He will report to
Peter Guenter in his new role as Executive Vice President, Global Commercial
Operations. David will join the Global Leadership Team and become Chairman of
the European Strategic Committee.
As Senior Vice President, Commercial Operations, Europe, David Loew will be
responsible for 38 countries organized into direct countries and Multi Country
Organizations. David will be responsible for defining the commercial strategy
for the region and lead its effective execution through more than 9,000
employees.
Peter Guenter, currently Senior Vice President, Europe, Sanofi declared:
"Europe remains a key strategic region for Sanofi, with a high level of
complexity and diversity of markets, facing critical challenges in a mature
environment. David's vast experience, international exposure and know how at
both country and corporate positions will be a significant addition to Sanofi
and make him ideally suited to lead our commercial operations in Europe."
David Loew will join Sanofi from Roche Pharmaceuticals where he is currently
Regional Head Eastern Europe, Middle East and Africa.
Biography of David Loew
Swiss born, David Loew, started his career with traineeships in the US at
Coopers & Lybrand and Hewlett Packard in 1990, before joining Roche in 1992 as a
sales representative in Vienna, Austria. He moved to Basel in 1993 for a
management development programme and then took up the position of Senior Product
Manager in France in 1995. Within two years, David was promoted to Marketing
Manager for transplantation and dialysis. In 1999 he was appointed Business
Director, Specialty Care in Mexico.
David was promoted in 2001 to global marketing roles - "Life Cycle Leader" - of
growing importance, splitting his time between Nutley, New Jersey and Basel,
Switzerland. He was instrumental in developing and launching several
indications of Xeloda and MabThera shaping the drugs successes.
Subsequently David took over the position as Oncology head.
After six years in marketing roles, David became General Manager Switzerland in
2007 and at the beginning of 2010, was appointed Global Chief Marketing Officer
/ Head of Global Product Strategy for the pharmaceuticals division of Roche. His
remit included the responsibility for all therapeutic areas of Roche, including
the area heads, life cycle and global brand teams, the global medical affairs
function, global pharmaceuticals economics and pricing. In early 2013, he was
appointed to his current role as Regional Head Eastern Europe, Middle East and
Africa.
David has a degree in Finance and Marketing and an MBA from the University of
St. Gallen (HSG). German is David's native tongue and he speaks English, French
and Spanish fluently.
About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to future
financial results, events, operations, services, product development and
potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that forward-
looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that may
be filed for any such product candidates as well as their decisions regarding
labelling and other matters that could affect the availability or commercial
potential of such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future approval and
commercial success of therapeutic alternatives, the Group's ability to benefit
from external growth opportunities, trends in exchange rates and prevailing
interest rates, the impact of cost containment policies and subsequent changes
thereto, the average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by Sanofi,
including those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year
ended December 31, 2012. Other than as required by applicable law, Sanofi does
not undertake any obligation to update or revise any forward-looking information
or statements.
Contacts:
Media Relations Investor Relations
Jean-Marc Podvin Sébastien Martel
Tel.: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45
mr@sanofi.com ir@sanofi.com
The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication.
Share this article